stockportfolio.pro
Stocks / IMMX vs RIGL
IMMX vs RIGL
Immix Biopharma, Inc. and Rigel Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Immix Biopharma, Inc. (IMMX) | Rigel Pharmaceuticals, Inc. (RIGL) | |
|---|---|---|
| Market cap | $0.6B | $0.6B |
| Revenue (latest FY) | $0 | $294.28M |
| Net income (latest FY) | $-29.44M | $367.02M |
| Revenue growth (5y CAGR) | — | 22.1% |
| Net margin | — | 124.7% |
| Return on equity | -31.4% | 93.8% |
| P/E ratio | — | 1.6 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 2 |
| Positive free cash flow | No | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open IMMX — free Open RIGL — freeFrequently asked questions
Which is bigger, IMMX or RIGL?
Rigel Pharmaceuticals, Inc. is larger by market capitalization — $0.6B versus $0.6B.
Which grows faster, IMMX or RIGL?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.